Dr. Harrison is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Duke Medicine Cir
Durham, NC 27710Phone+1 919-684-8111
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2007 - 2009
Tulane UniversityResidency, Internal Medicine, 2004 - 2007- Tulane University School of MedicineClass of 2004
Certifications & Licensure
NC State Medical License 2011 - 2025
WI State Medical License 2007 - 2011
LA State Medical License 2005 - 2007- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
- RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017) Start of enrollment: 2014 Mar 01
- Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis Start of enrollment: 2015 Jul 01
Publications & Presentations
PubMed
- Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospecti...Nrupen A Bhavsar, Michael R Harrison, Charles D Scales, Tian Zhang, Jesse Troy
European Urology Open Science. 2024-08-01 - Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The...Tian Zhang, Lauren Howard, Bridget F Koontz, Scott T Tagawa, Himanshu Nagar
European Urology Oncology. 2024-07-05 - 4 citationsImmune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.Wolfgang Beckabir, Mi Zhou, Jin Seok Lee, Steven P Vensko, Mark G Woodcock
Nature Communications. 2024-05-24
Press Mentions
Immunotherapy Agents Improve Outlook for Advanced Bladder CancerAugust 13th, 2019
Cabozantinib RCC Benefit Highlighted as Frontline Approval ApproachesNovember 15th, 2017- Advanced RCC Results Point to Potentially New Frontline TreatmentsOctober 4th, 2017
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
